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To evaluate the joint association of sodium and 
potassium urinary excretion (as surrogate measures 
of intake) with cardiovascular events and mortality, 
in the context of current World Health Organization 
recommendations for daily intake (<2.0 g sodium, 
>3.5 g potassium) in adults.
DESIGN
International prospective cohort study.
SETTING
18 high, middle, and low income countries, sampled 
from urban and rural communities.
PARTICIPANTS
103 570 people who provided morning fasting urine 
samples.
MAIN OUTCOME MEASURES
Association of estimated 24 hour urinary sodium 
and potassium excretion (surrogates for intake) 
with all cause mortality and major cardiovascular 
events, using multivariable Cox regression. A six 
category variable for joint sodium and potassium 
was generated: sodium excretion (low (<3 g/day), 
moderate (3-5 g/day), and high (>5 g/day) sodium 
intakes) by potassium excretion (greater/equal or less 
than median 2.1 g/day).
RESULTS
Mean estimated sodium and potassium urinary 
excretion were 4.93 g/day and 2.12 g/day, 
respectively. After a median follow-up of 8.2 years, 
7884 (6.1%) participants had died or experienced a 
major cardiovascular event. Increasing urinary sodium 
excretion was positively associated with increasing 
potassium excretion (unadjusted r=0.34), and only 
0.002% had a concomitant urinary excretion of 
<2.0 g/day of sodium and >3.5 g/day of potassium. 
A J-shaped association was observed of sodium 
excretion and inverse association of potassium 
excretion with death and cardiovascular events. For 
joint sodium and potassium excretion categories, 
the lowest risk of death and cardiovascular events 
occurred in the group with moderate sodium excretion 
(3-5 g/day) and higher potassium excretion (21.9% 
of cohort). Compared with this reference group, the 
combinations of low potassium with low sodium 
excretion (hazard ratio 1.23, 1.11 to 1.37; 7.4% 
of cohort) and low potassium with high sodium 
excretion (1.21, 1.11 to 1.32; 13.8% of cohort) 
were associated with the highest risk, followed by 
low sodium excretion (1.19, 1.02 to 1.38; 3.3% of 
cohort) and high sodium excretion (1.10, 1.02 to 
1.18; 29.6% of cohort) among those with potassium 
excretion greater than the median. Higher potassium 
excretion attenuated the increased cardiovascular 
risk associated with high sodium excretion (P for 
interaction=0.007).
CONCLUSIONS
These findings suggest that the simultaneous target 
of low sodium intake (<2 g/day) with high potassium 
intake (>3.5 g/day) is extremely uncommon. Combined 
moderate sodium intake (3-5 g/day) with high 
potassium intake is associated with the lowest risk of 
mortality and cardiovascular events.
Introduction
Consumption of sodium and potassium is essential 
to health, as neither are produced endogenously 
and both are necessary for critical physiological 
processes.1-3 Maintaining homeostasis requires a 
WHAT IS ALREADY KNOWN ON THIS TOPIC
Dietary guidelines recommend sodium restriction but increased potassium 
intake (WHO recommends <2.0 g/day and >3.5 g/day, respectively)
Studies evaluation the association of sodium intake have reported inconsistent 
findings, but many report a J-shaped association, while those evaluating 
potassium intake generally report a linear reduction in mortality with increasing 
potassium intake
Most observational studies have reported on the effects of sodium and 
potassium intake separately, although some have reported on the association of 
sodium:potassium ratio with clinical outcomes
WHAT THIS STUDY ADDS
The study findings question the feasibility of the WHO simultaneous target of 
low sodium intake (<2 g/day) with high potassium intake (>3.5 g/day), which was 
consumed by a very low proportion of the population.
The combination of moderate sodium intake (3-5 g/day) with higher potassium 
intake was associated with the lowest risk of mortality and cardiovascular events
The J-shaped association of sodium intake with mortality and cardiovascular 
events does not lend support to the current WHO recommendation to 
consume low sodium diets (<2.0 g/day), and it also argues against use of the 
sodium:potassium ratio
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mutual interdependence of sodium and potassium, 
meaning that their relation with health is necessarily 
linked.1-3 Despite these fundamental physiological 
considerations, current public health policy adopts 
markedly opposing guidance for sodium and 
potassium intake, with the World Health Organization 
recommending an extremely low sodium intake (<2 g/
day, whereas the current average intake is about 4 g/
day) but high potassium intake (>3.5 g/day, whereas 
the average intake is about 2 g/day) in the entire adult 
population.4-6 International data on the percentage 
of people with very low intakes of sodium and 
simultaneously high potassium intakes7 and the joint 
effects on health outcomes from large international 
epidemiological studies are limited.4 5 8 9
Current public health policy on targets for sodium 
intake is based primarily on small, and mostly 
short term, clinical trials evaluating the relation of 
changes in sodium and potassium intake with blood 
pressure.4 8 Although clinical trials have reported 
a decrease in blood pressure with a reduction in 
sodium intake,8 many prospective cohort studies 
have reported a J-shaped association of sodium intake 
and cardiovascular disease or mortality,10-16 with an 
increased risk emerging at sodium intakes <2.7 g/
day and >5 g/day.10 The increased cardiovascular 
risk associated with high sodium intake seems to 
be especially in those with hypertension,17 whereas 
the increased risk associated with low sodium 
intake might be mediated through activation of 
physiological systems to conserve sodium (eg, renin-
angiotensin-aldosterone system).18 In contrast, the 
association of potassium intake with blood pressure 
and cardiovascular disease is consistent, with a linear 
reduction in blood pressure and cardiovascular risk 
with increasing potassium intake reported in most 
studies.9 Some epidemiological studies report an 
interactive association of sodium and potassium 
intake with blood pressure, and other studies report 
use of sodium:potassium ratios for predicting risk of 
cardiovascular events and mortality.19-25 Whether 
a potential modifying effect of increased potassium 
intake is directly causal or simply a marker of improved 
diet quality,26 as diets rich in fruit and vegetables 
(which are associated with lower cardiovascular risk) 
are high in potassium, is uncertain.
In the Prospective Urban Rural Epidemiological 
(PURE) Study, we have previously reported on 
the intermediate term (3.7 years of follow-up)16 17 
association of sodium and potassium intake with 
mortality and cardiovascular events. In the current 
analyses, we further explore the association of sodium 
and potassium intake with death and cardiovascular 
disease in extended follow-up (eight years).
Methods
Study population
The PURE Study is a large scale epidemiological cohort 
study that has enrolled people (aged 35 to 70 years) 
residing in 628 urban and rural communities in low, 
middle, and high income countries (Bangladesh, 
India, Pakistan, Zimbabwe, Argentina, Brazil, Chile, 
Malaysia, Poland, South Africa, Turkey, China, 
Colombia, Iran, Canada, Sweden, Palestinian territories 
occupied by Israel, and United Arab Emirates).27-29 
The supplementary appendix describes the selection 
of participants. Recruitment began in January 2003. 
Participants provided written informed consent. For 
the current analysis, we included 103 570 participants 
from 18 countries who collected early morning fasting 
urine samples suitable for analysis, of which 103 200 
(99.6%) had follow-up information available (95% 
completed at least one follow-up visit). The Population 
Health Research Institute of Hamilton Health Sciences, 
Ontario, Canada coordinated the study.
Exposure assessments
A morning fasting midstream urine sample, collected 
from each participant, was frozen at −20ºC to −70ºC 
and shipped to a central laboratory in Canada, China, 
India, or Turkey. The samples were shipped at ambient 
temperature using the STP 250 ambient specimen 
shipping box (see supplementary appendix for a 
description of the methods used for performing urinary 
analyses). We used the Kawasaki formula to estimate 
24 hour urinary sodium and potassium excretion from 
a fasting morning sample, and these estimates have 
been validated previously versus measured with 24 
hour urine collection.30 31 An international validation 
study reported an intraclass correlation of Kawasaki 
formula to actual 24 hour urine collections of 0.71.31 
Therefore, we used the estimates derived from fasting 
morning urine as surrogates for sodium and potassium 
intake in the study. (The supplementary appendix 
provides summary details of validation of this 
approach.)
Ascertainment of outcomes
Standardised case report forms were used to capture 
major cardiovascular events (myocardial infarction, 
stroke, and heart failure), cancer, and death at follow-
up, which were adjudicated using standardised 
definitions.32 For the current analysis, we included all 
adjudicated outcome events in the PURE database up to 
September 2017. The primary composite outcome was 
all cause mortality or myocardial infarction or stroke 
or heart failure. Secondary outcomes were individual 
components of the primary composite outcome, and 
new diagnosis of cancer on follow-up.
Ascertainment of covariates
All participants completed baseline standardised 
questionnaires, which included detailed information 
on age, sex, lifestyle risk factors (eg, smoking, diet, 
physical activity, alcohol intake), comorbidities (eg, 
history of diabetes, hypertension, cardiovascular 
disease), physical measurements (blood pressure, 
heart rate, body mass index (BMI), waist:hip ratio), 
and laboratory measurement of lipoproteins (88%). 
A modified alternative healthy eating index (mAHEI) 
score was used to measure overall diet quality, with 
higher scores indicating a healthier diet.33
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Statistical analyses
Baseline differences in characteristics between study 
participants in different categories of estimated 
sodium and potassium excretion have been reported 
previously (see supplementary appendix).25 Restricted 
cubic spline plots were used to explore the shape of 
association between estimated sodium and potassium 
excretion and outcomes, fitting a restricted cubic 
spline function with four knots (5th, 35th, 65th, 
and 95th centiles).34 Our primary outcome measure 
was the composite of all cause mortality and major 
cardiovascular events (cardiovascular death, stroke, 
myocardial infarction, and heart failure). Secondary 
outcomes included individual components of the 
primary outcome.
Based on our restricted cubic spline plots for 
the primary outcome, and the results of previous 
analyses,13 16 we selected 4.00 to 4.99 g/day as the 
reference category for sodium excretion and <1.5 g/
day for potassium excretion. We modelled the time 
to event outcome using multivariable Cox regression 
proportional hazards analysis with mixed effect 
(centre included as a random effect variable to 
account for clustering by research site) to determine 
the association between estimated urinary sodium 
and potassium excretion and outcomes, using three 
sequential models. Model 1 (primary model) adjusted 
for age (included as spline function), sex, education, 
current and former alcohol intake (units weekly), 
diabetes mellitus, BMI, physical activity, history of 
cardiovascular events, use of cardiovascular drugs 
(blood pressure lowering, statins, or antidiabetics), 
history of tuberculosis, cancer, HIV, and current 
and former smoking, which constituted our 
primary multivariable model (with an additional 
model that included low density lipoprotein (LDL) 
cholesterol:high density lipoprotein (HDL) cholesterol 
ratio). Model 2 also included caloric intake, estimated 
potassium (or sodium) excretion, waist:hip ratio, and 
modified mAHEI. Model 3 also included history of 
hypertension, and baseline systolic and diastolic blood 
pressure and heart rate, which are in the putative 
causal pathway. We performed an analysis of the 
combined effects of sodium and potassium, in which 
we generated six categories for sodium excretion (low 
(<3 g/day), moderate (3-5 g/day), and high (>5 g/day)), 
and potassium excretion above and below the median 
(2.1 g/day). Three categories were selected for sodium 
excretion, as the estimated association was J-shaped, 
whereas two categories were selected for potassium 
excretion, as the association was linear in analyses. 
We also completed a stratified subgroup analysis of the 
association between sodium excretion and outcomes, 
stratified by groups of urinary potassium excretion and 
mAHEI divided at the tertiles. We tested for interactions 
between sodium excretion and potassium excretion 
and between sodium excretion and mAHEI score. As 
the association of sodium excretion and composite 
outcome was non-linear, we tested for interaction 
above and below median sodium excretion (ie, four 
tests for interaction), modelling the log hazard ratio as 
a piecewise linear function of sodium excretion; two 
connected lines above and below the median sodium 
excretion with different slopes could interact with 
the potassium and mAHEI subgroups. We completed 
an analysis of “usual” sodium intake, based on 
repeated measurement in 494 participants, employing 
methodology used in previous publications.25
To minimise the potential for reverse causation, 
we conducted sensitivity analyses that excluded 
participants with a final follow-up or outcome event 
within the first three years of baseline. To assess the 
changes in hazard for the primary outcome with 
simultaneous changes in sodium and potassium 
excretion, the hazard ratio was modelled using a 
two dimensional natural cubic spline. For each of 
sodium and potassium, two knot points were selected 
at the tertiles of the variable’s sample distribution. 
This resulted in a grid of four knot points on a two 
dimensional (sodium and potassium) spline surface. 
The Cox proportional hazard model then included 
(along with other covariates) natural cubic spline 
variables for both sodium and potassium separately 
and for interaction terms between these spline 
variables. To visualise the two dimensional change 
in hazard, and the putative interaction effect between 
sodium and potassium, estimated hazard ratios were 
plotted for each observed pair sodium and potassium 
values in the analysis dataset (a heat map). The 
reference for plotted hazard ratios was the hazard at 
the median levels of sodium (4.70 g) and potassium 
(2.1 g).
All analyses were conducted using R Version 3.4.4 
(R Foundation for Statistical Computing, Vienna, 
Austria).
Patient and public involvement
No patients were involved in setting the research 
question or outcome measures, or in the design and 
implementation of the study.
Results
In total, 103 570 participants were included, of whom 
41.8% were from China. In the overall population, 
mean estimated 24 hour sodium excretion was 4.9 
g and mean estimated potassium excretion 2.1 g. 
(see supplementary table 1) After a median duration 
of 8.2 years (interquartile range 6.0-9.4) there were 
4524 deaths, 4889 with a major cardiovascular event 
(1893 myocardial infarctions, 2526 strokes, 534 heart 
failure, and 1293 cardiovascular deaths), and 7884 
had either a cardiovascular event or died, and 3263 
had a diagnosis of cancer.
Mortality and cardiovascular events
Estimated sodium excretion
Compared with estimated sodium excretion of 4.00 
to 4.99 g/day (the reference group), higher estimated 
sodium excretion (>7 g/day) was associated with 
a greater risk of the primary composite outcome 
(hazard ratio 1.23, 95% confidence interval 1.12 
to 1.34), all cause mortality (1.36, 1.20 to 1.53), 
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major cardiovascular events (1.20, 1.08 to 1.34), 
cardiovascular death (odds ratio 1.49, 95% confidence 
interval 1.21 to 1.84), and fatal stroke (hazard ratio 
1.76, 95% confidence interval 1.28 to 2.41) on 
multivariable analysis (table 1, supplementary table 
2, fig 1).
Compared with estimated sodium excretion of 4.00 
to 4.99 g/day, lower estimated sodium excretion (<3 g/
day) was associated with a greater risk of the primary 
composite outcome (hazard ratio 1.19, 95% confidence 
interval 1.09 to 1.30), all cause mortality (1.26, 1.12 
to 1.41), major cardiovascular events (1.19, 1.06 to 
1.33), cardiovascular death (1.35, 1.09 to 1.69), and 
stroke (1.24, 1.05 to 1.46); supplementary table 2. No 
association was found between sodium excretion and 
cancer or cancer mortality (see supplementary table 2).
Estimated potassium excretion
Compared with estimated potassium excretion of 
<1.5 g/day, higher estimated potassium excretion 
was associated with a lower risk of mortality and 
cardiovascular events (0.83, 0.73 to 0.94 for >3 g/day) 
on multivariable analysis (fig 2, supplementary table 
3). This associated reduction in hazard was greater 
for mortality risk (0.71, 0.60 to 0.85) than for major 
cardiovascular events (0.87, 0.75 to 1.02). No apparent 
association was found between potassium excretion 
and cancer or cancer mortality (see supplementary 
table 3).
Combined sodium and potassium excretion
Table 2 shows the association of sodium excretion 
with the primary composite outcome, categorised by 
joint sodium and potassium excretion (six categories). 
The lowest risk of death and cardiovascular events 
occurred in the group with moderate sodium excretion 
(3-5 g/day) and higher potassium excretion (21.9% 
of cohort). Compared with this reference group, the 
combinations of low potassium with low sodium 
excretion (hazard ratio 1.23, 95% confidence interval 
1.11 to 1.37; 7.4% of cohort) and low potassium with 
high sodium excretion (1.21, 1.11 to 1.32; 13.8% of 
cohort) were associated with the highest risk, followed 
by high sodium excretion (1.10, 1.02 to 1.18 (29.6% of 
cohort)) and low sodium excretion (1.19, 1.02 to 1.38; 
3.3% of cohort)) among those with potassium excretion 
above the median. Moderate sodium excretion with low 
potassium excretion was associated with an increased 
risk of the primary outcome (1.10, 1.01 to 1.19; 24.0% 
of cohort), compared with reference. Few participants 
(0.002%) had both very low sodium excretion (<2 g/
day) and high potassium excretion (>3.5 g/day)—a 
target recommended by nutrition guidelines—so 
that the risk in this subgroup could not be estimated 
reliably (0.2% for potassium >2.63 g/day, assuming 
that about 75% of potassium is excreted in the urine,35 
and sodium excretion <2.3 g/day). Figure 3 reports 
results of a heat map that combines multivariable 
cubic splines of the association of both sodium 
excretion and potassium excretion with the primary 
outcome, with median excretion as reference category. 
Table 3 and figure 4 show a stratified analysis by thirds 
of potassium excretion, supporting a lower relative risk 
associated with higher sodium excretion among those 
with higher potassium excretion. Test for interaction 
of higher sodium excretion (above the median) and 
potassium excretion was significant (P=0.007) but for 
lower sodium excretion and potassium excretion was 
not significant (P=0.94).
Sodium excretion and diet quality (mAHEI)
Figure 5 and table 3 report a stratified analysis by 
mAHEI thirds, which suggest a lower magnitude of risk 
for the association of sodium excretion with mortality 
and cardiovascular events among those with higher 
diet quality scores, although P for interactions were 
not significant (P=0.87 for below median excretion 
and P=0.30 above median excretion).
Table 1 | Association of estimated urinary sodium excretion with mortality and cardiovascular events. Values are hazard ratios (95% confidence 
intervals)
Variables
Estimated sodium excretion (g/day)
<3 (n=11 002) 3-3.99 (n=21 417) 4-4.99 (n=26 012) 5-5.99 (n=21 093) 6-6.99 (n=12 458) ≥7 (n=11 218)
No of deaths and cardiovascular events 949 1562 1816 1640 964 953
Univariate* 1.23 (1.14 to 1.34) 1.05 (0.98 to 1.12) 1.00 1.09 (1.02 to 1.17) 1.07 (0.99 to 1.16) 1.16 (1.07 to 1.26)
Multivariable (primary)† 1.19 (1.09 to 1.30) 1.06 (0.99 to 1.14) 1.00 1.08 (1.00 to 1.16) 1.07 (0.98 to 1.16) 1.23 (1.12 to 1.34)
Multivariable (+diet) 1.16 (1.05 to 1.27) 1.06 (0.98 to 1.14) 1.00 1.09 (1.01 to 1.17) 1.08 (0.99 to 1.18) 1.26 (1.15 to 1.39)
Multivariable (+blood pressure/heart 
rate)
1.15 (1.04 to 1.28) 1.06 (0.98 to 1.14) 1.00 1.08 (1.00 to 1.16) 1.06 (0.96 to 1.16) 1.17 (1.06 to 1.28)
Multivariable‡ (excluding CVD, diabetes, 
smoker, and cancer)§
1.16 (1.03 to 1.31) 1.04 (0.94 to 1.15) 1.00 1.08 (0.98 to 1.19) 1.06 (0.95 to 1.18) 1.12 (0.99 to 1.25)
Multivariable‡ (excluding events in first 
3 years)
1.20 (1.07 to 1.33) 1.11 (1.02 to 1.21) 1.00 1.12 (1.03 to 1.21) 1.09 (0.99 to 1.20) 1.17 (1.06 to 1.30)
Multivariable‡ (primary+lipids) 1.17 (1.06 to 1.29) 1.06 (0.98 to 1.15) 1.00 1.07 (0.99 to 1.16) 1.05 (0.96 to 1.15) 1.24 (1.13 to 1.36)
CVD=cardiovascular disease.
Major cardiovascular events include cardiovascular mortality, myocardial infarction, stroke, and heart failure.
Primary model includes the following covariates at baseline: age, sex, education, alcohol intake, diabetes mellitus, body mass index, a history of cardiovascular events, cancer and chronic 
obstructive pulmonary disease, cardiovascular drugs at baseline, HIV, tuberculosis, physical activity level, and smoking status and dosage. Dietary variables: addition of caloric intake, potassium 
intake, waist:hip ratio, and modified alternative healthy eating index score. Blood pressure variables: baseline systolic blood pressure and history of hypertension. Low density lipoprotein 
cholesterol:high density lipoprotein cholesterol ratio available in 88% of cohort.
*Univariate analysis using Cox proportional hazards model with a random effect for study centre (to address clustering of data) includes 103 200 participants with follow-up data.
†Includes 90% of all participants in univariate model, 10% of participants had missing data for at least one covariate, we did not undertake imputation for missing data.
‡Adjusted for variables in primary model.
§Excludes those with baseline history of cardiovascular disease, diabetes mellitus, current smoking, and cancer (history of or within first year of follow-up).
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Composite outcome

































































































































































Fig 1 | Restricted cubic spline plot of association of estimated 24 hour urinary sodium excretion with composite 
of all cause mortality and major cardiovascular events, mortality, and major cardiovascular events (composite of 
cardiovascular death or myocardial infarction or stroke or heart failure). Plots adjusted for age (included as spline 
function), sex, education, current and former alcohol intake (units weekly), diabetes mellitus, body mass index, 
physical activity, history of cardiovascular events, use of cardiovascular drugs (blood pressure lowering, statins, 
or antidiabetics), history of tuberculosis, cancer, HIV, and current and former smoking. Dashed lines indicate 95% 
confidence intervals. Median intake is reference standard (4.9 g/day). Salt approximates 2.5×sodium g/day. Spline 
curve was truncated at 10 g/day in all plots
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Composite outcome
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Fig 2 | Restricted cubic spline plot of association of estimated 24 hour urinary potassium excretion with composite 
of all cause mortality and major cardiovascular events, mortality, and major cardiovascular events (composite of 
cardiovascular death, myocardial infarction, stroke, and heart failure). Plots adjusted for age (included as spline 
function), sex, education, current and former alcohol intake (units weekly), diabetes mellitus, body mass index, 
physical activity, history of cardiovascular events, use of cardiovascular drugs (blood pressure lowering, statins, or 
antidiabetics), history of tuberculosis, cancer, HIV, and current and former smoking. Spline was truncated at 4 g/day 
in all plots
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Sensitivity analyses
Exclusion of participants who had events in the first 
three years of follow-up, and excluding those with 
baseline cardiovascular disease, cancer (or cancer in first 
year of follow-up, diabetes, and current smoking), did 
not materially affect findings. (table 1) Supplementary 
figure 1 reports the association of “usual” 24 hour 
urinary sodium excretion and clinical outcomes.
Discussion
In this large international prospective cohort study, we 
investigated the joint association of estimated sodium 
and potassium urinary excretion (surrogates for intake) 
and clinical outcomes over a median follow-up of 8.2 
years. Overall, the lowest risk of death and adverse 
clinical events was seen in those with estimated sodium 
excretion between 3 and 5 g/day, and with the highest 
potassium excretions (see fig 1 and table 2). Both 
higher and lower levels of estimated sodium excretion 
were associated with higher cardiovascular risk, 
thereby describing a J-shaped curve for association, 
whereas the association of potassium excretion and 
mortality or cardiovascular risk was inverse and linear. 
Higher potassium intake attenuated the increased 
cardiovascular risk associated with high sodium 
intake, and the association of high sodium excretion 
with cardiovascular risk was most prominent in those 
with low potassium intake.
Comparison with other studies
Potassium, the most abundant intracellular cation, 
and sodium, the most abundant extracellular cation, 
are inextricably linked, with their exchange required 
for membrane potential of cells (Na-K-ATPase) and 
their inter-reliance on diet and kidneys to maintain 
homeostasis.23 We found that the association 
of higher sodium excretion with cardiovascular 
risk was lower among those with higher urinary 
potassium excretion. While previous studies have 
reported that higher potassium intake diminishes the 
association of higher sodium intake with increased 
blood pressure, no study has been sufficiently large 
to show a statistically significant modifying effect of 
sodium and potassium intake with cardiovascular 
events and mortality.19-24 In our analyses, extremes 
of sodium excretion (both high and low) in a setting 
of low potassium excretion are associated with the 
highest risk of death and cardiovascular events (see 
fig 1 and table 2). Low potassium intake not only 
results in potassium retention by the kidneys, but also 
induces sodium retention.36 37 Renal conservation 
of sodium in the setting of low potassium diets is 
mediated through WNK (“with no lysine(K)”) kinases 
activating the thiazide sensitive sodium-chloride 
cotransporter, leading to greater increases in blood 
pressure with increasing sodium intake.38 39 Low 
potassium intake might also reflect poorer diet quality, 
particularly lower intake of fruits and vegetables, and 
the association of sodium intake with cardiovascular 
risk might be confounded by foods that independently 
affect cardiovascular risk. Our subgroup analysis 
by diet quality (modified alternative healthy eating 
index, mAHEI) would lend some support to this 
contention, whereby the magnitude of association of 
sodium excretion with cardiovascular risk appeared 
Table 2 | Association of joint urinary sodium and potassium excretion with mortality and cardiovascular events
Estimated potassium excretion (g/day)
Estimated sodium excretion (g/day)
<3 3-5 >5
<median, 2.1 g/day:
 Hazard ratio (95% CI) 1.23 (1.11 to 1.37) 1.10 (1.01 to 1.19) 1.21 (1.11 to 1.32)
 Event proportion* 716/7582 (9.4%) 1924/24741 (7.8%) 1260/14259 (8.8%)
≥median, 2.1 g/day:
 Hazard ratio (95% CI) 1.19 (1.02 to 1.38) 1.00 (reference) 1.10 (1.02 to 1.18)
 Event proportion* 233/3420 (6.8%) 1454/22 688 (6.4%) 2297/30 510 (7.5%)
Adjusted for age (included as spline function), sex, education, current and former alcohol intake (units weekly), diabetes mellitus, body mass index, 
physical activity, history of cardiovascular events, use of cardiovascular drugs (blood pressure lowering, statins, or antidiabetics), history of tuberculosis, 
cancer, HIV, and current and former smoking.
*Event proportion for composite outcome of major cardiovascular events or mortality.
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Fig 3 | Heat map of risk for composite of cardiovascular events or death showing lowest 
risk in region of moderate sodium intake 3-5 g/day and higher potassium intake and 
highest risk in region of extremes of sodium excretion and low potassium excretion. The 
reference hazard for these hazard ratios was set at a value of sodium daily excretion/
intake of 5.00 g and potassium daily excretion/intake of 2.25 g (median excretion of 
sodium and potassium), marked as X. The overlaid lines represent joint distribution 
quartiles; each region contains a quarter of the analysed participants. r=0.34
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lower among those consuming the highest third of 
diet quality, although formal tests of interaction were 
not statistically significant (table 3). Therefore, higher 
potassium intake could directly affect cardiovascular 
and mortality risks or is a marker of increased intake 
of healthier food items that are rich in potassium (eg, 
fruit, vegetables, nuts), or a combination of both. The 
DASH-Sodium trial reported a lower antihypertensive 
effect of reducing sodium intake, in the setting of 
higher potassium intake, supporting the contention 
that the association of higher sodium intake with 
cardiovascular health might be modified by potassium 
intake.40 A small cluster randomised controlled 
trial (five centres), which replaced table salt with 
low sodium salt substitute (partially replaced with 
potassium chloride) reported a reduced cardiovascular 
risk in those centres randomised to salt substitution, 
although findings were not conclusive owing to 
methodological limitations of the trial.41 An ongoing 
large cluster randomised controlled trial in China, 
evaluating the use of salt substitutes (potassium 
chloride substituted for sodium chloride) is expected 
to provide a more definitive answer.42 However, these 
trials evaluate simultaneous increased potassium 
intake with a reduction of high sodium intake to 
moderate intake levels, and it is unlikely to inform 
whether a very low sodium intake (<2.0 g/day) is 
beneficial or harmful. Finally, increased cardiovascular 
risk might also be mediated through activation 
of numerous adaptive renal and neuroendocrine 
mechanisms to maintain balance of both electrolytes, 
in response to low potassium and low dietary sodium, 
especially activation of the renin-aldosterone-
angiotensin system,18 the activation of which is 
known to increase cardiovascular risk. Collectively, 
these data suggest that the health impact of these two 
cations cannot be easily assessed separately. However, 
our findings would argue against an isolated use of 
a sodium:potassium ratio, because of the J-shaped 
association of sodium intake and clinical outcomes 
and the ratio does not take account of absolute intake 
levels. For example, the combination of moderate 
intake of sodium and potassium is associated with 
lower cardiovascular risk than combined low intake 
of both sodium and potassium, despite the same 
sodium:potassium ratio.
Public health implications
Guidelines for dietary recommendations, targeting the 
entire population, should be both feasible and based 
on clear high quality evidence of improved health 
outcomes.45 Our results suggest that a combined 
strategy of low sodium intake (<2.0 g/day), while 
simultaneously increasing potassium intake to >3.5 g/
day, is unrealistic, as only 0.002% of the population 
were in this range (0.2% for potassium excretion of 
2.62 g/day, if we assume that about 75% of potassium 
is excreted in urine35). These estimates are consistent 
with reports from studies in the United Kingdom 
(0.1%), United States (0.3%), Mexico (0.15%), and 
France (0.5%).7 In each of these studies, estimates of 
sodium intake were based on questionnaire, which 
is known to underestimate intake, meaning that the 
proportion of the population achieving actual target 
may be lower than reported.7 This finding also meant 
that we were unable to evaluate the association of 
these joint dietary intake levels with health outcomes, 
as numbers of participants were insufficient despite 
the large sample size. We observed a linear relation 
between increased sodium and potassium intake, a 
consistent finding of other studies.7 20 These findings 
question the feasibility of increasing potassium intake 
while achieving very low sodium intake of populations 
through modifying diets. While small phase II clinical 
trials, such as DASH-Sodium,40 have achieved these 
targets in the short term, they required complete 
control of dietary intake, which is impractical in free 
living populations. In contrast, the PREDIMED study,43 
which promoted increased intake of potassium 
containing foods (fruit, vegetables, nuts) with 
greater adherence to the Mediterranean diet, without 
focusing on low sodium intake, reported a statistically 
significant reduction in cardiovascular disease and 
mortality, and adherence to a Mediterranean diet has 
Table 3 | Association of estimated urinary sodium excretion with mortality and cardiovascular events (subgroup analysis). Values are hazard ratio (95% 
confidence interval)
Tertiles
Estimated sodium excretion (g/day)
P for interaction<3 (n=11 002) 3-3.99 (n=21 417) 4-4.99 (n=26 012) 5-5.99 (n=21 093) 6-6.99 (n=12 458) ≥7 (n=11 218)
Potassium excretion (g/day):




1.8-2.3 1.16 (0.97 to 1.38) 1.11 (0.97 to 1.26) 1.00 1.16 (1.03 to 1.31) 1.17 (1.01 to 1.36) 1.47 (1.26 to 1.71)
>2.3 1.12 (0.91 to 1.39) 1.02 (0.88 to 1.18) 1.00 1.08 (0.95 to 1.22) 1.01 (0.88 to 1.16) 1.11 (0.96 to 1.27)
Modified alternative healthy eating index score:




31.3-38.4 1.24 (1.06 to 1.46) 1.09 (0.96 to 1.25) 1.00 1.14 (1.01 to 1.30) 1.12 (0.97 to 1.30) 1.22 (1.05 to 1.43)
>38.4 1.09 (0.92 to 1.29) 1.03 (0.90 to 1.17) 1.00 1.00 (0.88 to 1.14) 0.99 (0.85 to 1.14) 1.06 (0.91 to 1.23)
Adjusted for age (included as spline function), sex, education, current and former alcohol intake (units per week), diabetes mellitus, body mass index, physical activity, history of cardiovascular 
events, use of cardiovascular medications (blood pressure lowering, statins, or antidiabetics), history of tuberculosis, cancer, HIV, and current and former smoking.
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Fig 4 | Association of urinary sodium excretion within tertiles of urinary potassium excretion. P for interaction is 
significant (P=0.007) for urinary potassium excretion×urinary sodium excretion above median intake, with lower 
magnitude of association with higher urinary potassium excretion. Plots adjusted for age (included as spline 
function), sex, education, current and former alcohol intake (units weekly), diabetes mellitus, body mass index, 
physical activity, history of cardiovascular events, use of cardiovascular drugs (blood pressure lowering, statins, or 
antidiabetics), history of tuberculosis, cancer, HIV, and current and former smoking
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Fig 5 | Association of urinary sodium excretion within tertiles of modified alternative healthy eating index (mAHEI) 
score. P for interactions not significant. Plots adjusted for age (included as spline function), sex, education, 
current and former alcohol intake (units weekly), diabetes mellitus, body mass index, physical activity, history of 
cardiovascular events, use of cardiovascular drugs (blood pressure lowering, statins, or antidiabetics), history of 
tuberculosis, cancer, HIV, and current and former smoking
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an inconsistent correlation with sodium intake.44 45 
In addition, a recent analysis of the NHANES study 
reported that sodium intake >2.3 g/day was associated 
with better diet quality, compared with diets of less 
than 2.3 g/day, meaning that improving dietary quality 
is likely to be easier to achieve within a moderate 
sodium intake range.46 These considerations raise 
considerable doubts about the feasibility and assumed 
cardiovascular effects of current recommendations to 
reduce sodium intake to very low levels (<2 g/day), 
which may counteract achieving other dietary targets 
and improving overall dietary quality.
Strengths and limitations of this study
Our estimate of sodium intake was based on a baseline 
measurement of sodium intake, derived from fasting 
morning urine samples, rather than repeated 24 hour 
urinary collections, which would be considered the 
reference standard for estimating usual sodium and 
potassium intake. However, our approach has been 
validated in an international study, against actual 
24 hour urine estimates of sodium and potassium 
excretion.31 Other formula based approaches have 
been developed for estimating 24 hour urinary sodium 
and potassium excretion, and one study reported that 
the Kawasaki formula was associated with the largest 
bias compared with actual 24 hour urine collections. 
In that study by Cogswell et al,47 however, a non-
fasting spot urine sample was used, which would be 
expected to produce biased over-estimates since the 
Kawasaki formula was developed and validated for a 
fasting urine sample, best reflecting basal excretion. 
In another study,48 which used an appropriate fasting 
sample, the Kawasaki formula approach was reported 
to be associated with least biased estimates (versus 
other formula) compared with actual 24 hour urine. 
Further evidence of the construct validity of our 
approach is the relation of estimated 24 hour urine 
estimates of sodium excretion to blood pressure 
(2.11/0.78 mm Hg/g increase in estimated 24 hour 
urinary sodium excretion), which are consistent with 
estimates reported in randomised controlled trials of 
sodium reduction.25
Relating a single time-point estimate of sodium and 
potassium intake to long term follow-up of death and 
cardiovascular events might be problematic if there are 
interval changes in dietary intake over time, and where 
repeated dietary measures are required to reduce 
the risk of regression dilution bias. Our approach is 
consistent with many other large epidemiological 
studies of sodium and potassium intake and analogous 
to epidemiological studies relating blood pressure, 
glucose, and cholesterol to clinical outcomes. For 
example, the correlation of office blood pressure and 
24 hour ambulatory blood pressure and of fasting 
glucose to glycated haemoglobin (HbA1c), is similar 
to the correlation we report for formula derived 
estimates.31 We chose this practical approach to 
estimating population level sodium and potassium 
intake in the PURE study, which includes a large 
representative population of participants from high, 
middle, and low income countries. We deemed 
actual 24 hour collections to be unfeasible in many 
low income settings and expected to have a greater 
risk selection bias due to non-completion of 24 hour 
collections. For example, in a recent NHANES study,49 
completion rates for 24 hour urine samples were about 
75%, and completers differed from non-completed for 
age, sex, ethnicity, body mass index, and hypertension 
status. For these reasons, WHO suggests50 the use of 
formula derived estimates of sodium and potassium 
intake in population level studies monitoring intakes 
over time. Among studies reporting on temporal 
changes of sodium intake over time, there is stability 
in mean intake of countries,6 51 especially those with 
mean sodium intake in the moderate range (3-5 g/day), 
whereas some countries with high mean intakes (>5 g/
day) have reported reductions in mean intake levels 
(eg, China, Finland),52 which means that interval 
changes in sodium intake are less likely to influence 
our findings in the low to moderate range of sodium 
intake but could reduce the magnitude of association 
in the higher sodium intake range.
Reverse causation has been a criticism of 
prospective cohort studies evaluating the association 
of diet and clinical outcomes, which may also occur 
when people reduce their sodium intake because 
of illness or based on medical recommendations. 
Alternatively, it may occur when people with a history 
of cardiovascular disease or risk factors, who are at 
increased cardiovascular risk, reduce their sodium 
intake on medical recommendations. In the PURE 
study, a few participants had previous cardiovascular 
disease, and our findings were not materially altered 
with their exclusion. Moreover, in the current analyses 
the exclusion of participants with cancer or diabetes 
or who were current smokers or those who had events 
in the first three years of follow-up did not materially 
alter findings. Additionally, we did not find an 
increased risk of death due to cancer with low sodium 
intake. Finally, given the observational nature of the 
study, residual confounding is a potential limitation. 
However, we adjusted for all major confounders of the 
association between sodium and potassium intake and 
cardiovascular events. Strengths of our study include 
the large representative international population in 
the PURE study, completeness of follow-up, rigorous 
approach to measurement of baseline variables, and 
adjudicated outcome clinical events.
Conclusions
Our findings suggest that a simultaneous target of low 
sodium (<2 g/day) with high potassium intake (>3.5 
g/day) in the population is extremely uncommon. 
The combination of moderate sodium intake (3-5 g/
day) with high potassium intake is associated with 
the lowest risk of mortality and cardiovascular events, 
whereas extremes of sodium intake combined with 
low potassium urinary excretion were associated with 
the highest cardiovascular risk. Our data support 
population wide increases in dietary potassium intake, 
with a population specific (ie, sodium intakes >5 g/
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day) reduction of sodium intake, embedded within an 
overall healthy dietary pattern.
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